Efficacy and Safety of Gefitinib in Patients with Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis of Randomized Controlled Trials

<p>PFS between gefitinib and no gefitinib group in patients with advanced head and neck cancer (HR 0.84; Z=1.62; P=0.11).</p>

Journal of Oncology

fig4

Figure 4

Figure 4: Efficacy and Safety of Gefitinib in Patients with Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis of Randomized Controlled Trials 

Figure 4 | Efficacy and Safety of Gefitinib in Patients with Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis of Randomized Controlled Trials 